

Full Length Research Paper

Anti-aggregation effects of thymoquinone against Alzheimer's β -amyloid *in vitro*

Ismail Norsharina¹, Ismail Maznah^{1,2,*}, Shahid Iqbal^{1,3}, Latiffah A. Latiff^{2,4}

¹Nutrigenomics and Nutricosmeceuticals Programme, Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

²Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

³Department of Chemistry, University of Sargodha, Sargodha-40100, Pakistan.

⁴Therapeutic and Epidemiology Programme, Laboratory for Cancer Research UPM-MAKNA, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

Accepted 9 March, 2011

Beta amyloid peptide ($A\beta$) aggregation has been identified as one of the major causes of neurodegenerative processes in Alzheimer's disease (AD). Despite recent improvements in the symptomatic therapy of cholinergic drugs; development of an effective therapeutic approach, that may interfere directly with $A\beta$ aggregation in the central nervous system, is desperately required. Thymoquinone (TQ) is a bioactive compound isolated from *Nigella sativa*, which has been reported to be possessing various pharmacological attributes. The effects of TQ on the formation of $A\beta_{1-40}$ were studied spectrophotometrically, over a duration of 16 days at pH 7.2 and 37°C. The inhibitory properties of TQ were compared with tannic acid (TA). Thymoquinone and TA, with IC_{50} of 0.1 and 29 μ M at day 0 (within 5h), respectively, inhibited $A\beta$ aggregation in a dose-dependent way at different concentrations, that is 1, 10 and 50 μ M. However, at day 16, IC_{50} of TQ and TA were found to be 0.2 and 0.01 μ M, respectively. In electron microscopic study, TQ, co-incubated with $A\beta_{1-40}$, reduced the numbers of fibrils in some degree with shorter fibrils and small amorphous aggregates. Pretreated TQ protected cytotoxic effects of $A\beta_{1-40}$ on primary cultured cerebellar granule neurons (CGNs). Therefore, TQ might have a direct interaction with $A\beta$ resulting in prevention of $A\beta$ aggregation and mediating its neuroprotective effects; thus may have potential in the therapeutic development of AD.

Key words: Anti-aggregation, β -amyloid, thymoquinone, tannic acid, Alzheimer's disease.

INTRODUCTION

Alzheimer's disease is ranked among the major causes of dementia among the elderly population (Sudhir, 2004). So far, only four drugs, that is, acetylcholinesterase (AChE) inhibitors; tacrine (Cognex®), donepezil (Aricept®), rivastigmine (Reminyl®) and memantine (Namenda®), have been approved by U.S. Food and

Drug Administration for the treatment of Alzheimer's disease (AD) patients. But these drugs can only treat the cognitive and behavioral symptoms of AD (Anekonda and Reddy, 2005), causing some side effects such as hepatotoxicity and peripheral cholinergic effects (Benzi and Moretti, 1998). The main pathological hallmarks of

*Corresponding author. Email: maznah@medic.upm.edu.my, myhome.e@gmail.com. Tel: +603-89472115. Fax: +603-89472116.

AD are senile plaques and neurofibrillary tangles in patient brain (Yankner, 1996; Selkoe, 1999). The major constituent of senile plaques is A β peptide with 39 to 43 amino acids, which is the by-product of amyloid precursor protein (Hardy and Higgins, 1992). A β ₁₋₄₀, A β ₂₅₋₃₅ and A β ₁₋₄₂ have been reported to be neurotoxic to neuronal primary culture and cell lines (Irie and Keung, 2003; Jeong et al., 2005; Yu et al., 2005; Lai et al., 2006). Their toxic effects have been contributed due to aggregation of A β in the forms like oligomers (Roher et al., 1996), protofibrils and fibrils (Ward et al., 2000). Amyloid fibrils and oligomers, which are formed via self-assembly of peptide and protein monomers, have been found to be associated with a crucial process in the pathogenesis of AD (Harper and Lansbury, 1997; Hensley et al., 1994).

Although there are no effective treatments for AD at the moment, but many therapeutic target molecules have been reported to be directly interfering with the formation, aggregation, deposition and clearance of beta amyloid peptide (A β) (Ono et al., 2006a). Among the candidate molecules, non-steroidal anti-inflammatory drugs (Hirohata et al., 2005) and anti-Parkinsonian agents (Ono et al., 2006a) are quite common. Since significant studies have demonstrated that oxidative stress may play a key role in neurodegeneration of AD (Grundman and Delaney, 2002), number of antioxidative compounds have been determined to protect neurons from A β toxicity *in vitro* (Kumar and Gupta, 2003), like lyophilized red wine (De Ruvo et al., 2000), grape polyphenols (Sun et al., 1999), quercetin (Shutenko et al., 1999) and (+)-catechin (Inanami et al., 1998). Moreover, many antioxidant compounds have also been reported to be possessing the direct inhibitory properties towards A β fibril formation, some of these identified compounds include polyphenols such as resveratrol and piceid (Riviere et al., 2007), curcumin and its analog rosmarinic acid (Ono et al., 2004a), myricetin (Ono et al., 2003), nordihydroguaiaretic acid and rifampicin (Naiki et al., 1998). Nevertheless, resveratrol diglucoside, piceatannol, astringine and viniferin exerted less inhibition in comparison to curcumin (Riviere et al., 2007).

Intake of wine containing polyphenols has been reported to be responsible for lowering the risks of AD (Luchsinger and Mayeux, 2004). On the other hand, lipophilic antioxidants, vitamin A (Ono et al., 2004) and coenzyme Q₁₀ (Ono et al., 2005), α -lipoic acid and its metabolic product, that is dihydrolipoic acid (Ono et al., 2006b) exhibited the formation of A β fibril. Tannins are commonly found in plants and herbs and are reported to be exhibiting much stronger inhibitory effects on lipid peroxidation as compared to vitamin E (Okuda et al., 1983). Previous studies have indicated that tannic acid (TA) prevented the development of AD through both modes; by scavenging the reactive oxygen species and inhibiting the deposition of fibril A β in the brain (Ono et

al., 2004c).

Thymoquinone (TQ) is a bioactive constituent of *Nigella sativa* and is well-known for its different biological activities such as antioxidant, anti-inflammatory, anti-microbial, anti-tumor, immunomodulatory, hypertension, anti-nociceptive, uricosuric, choleric, anti-fertility, anti-diabetic, and anti-histaminic (Salem, 2005). But no report describing the inhibition potential of TQ for A β fibril formation and aggregation has been presented so far. In view of the fact that increasing number of people across the globe are switching towards use of herbal medicines as supplements for treatment of different diseases, it would be of immense significance to explore the potential of a well documented plant based bioactive compound or herbal medicine as a neuroprotective agent (Lai et al., 2006).

In the present study, inhibitory effects of TQ in comparison to tannic acid (TA) on A β fibril formation have been investigated. UV-visible spectroscopic measurements and electron microscopy have been employed at pH 7.2 and 37°C for 16 days *in vitro*. The neuroprotective effects of TQ were examined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay, lactate dehydrogenase (LDH) release assay and the caspases-3, -8 and -9 activations. This work will contribute a new source of botanical origin for preventing the aggregation of A β to the existing database.

MATERIALS AND METHODS

Chemicals

A β ₁₋₄₀ peptide, dimethyl sulfoxide (DMSO), TQ, TA and other chemicals were purchased from Sigma-Aldrich (St.Louis, MO, USA).

Preparation of A β ₁₋₄₀ peptide, TQ and TA solutions

Stock solution of A β ₁₋₄₀ peptide (0.23 mM) was prepared by solubilizing the lyophilized peptide in phosphate buffered saline (PBS), pH 7.2. All the steps were carried out at 4°C to prevent the polymerization of A β ₁₋₄₀. Thymoquinone was dissolved in dimethyl sulfoxide (DMSO), while TA in distilled water to prepare respective stock solutions of 0.9 mM. The stock solution was further diluted to different concentrations of 1, 10 and 50 μ M and stored at -20°C. To study the kinetics of A β ₁₋₄₀ aggregation, experiments were carried out using a solution mixture containing 80 μ l of 0.8 mM PBS (pH 7.2) and 10 μ l of 5, 10, 25, 50 or 100 μ M A β ₁₋₄₀. This solution mixture was sonicated for 1 min to ensure that no peptide aggregation was formed. Ten microliters of 0.1% DMSO were added to this solution to create the same conditions as in presence of TQ, which was solubilized in 0.1% DMSO. To study the inhibitory activity of TQ and TA on A β aggregation, the mixture solution was prepared by adding 80 μ l of 0.8 mM PBS (pH 7.2), 10 μ l of 50 μ M A β ₁₋₄₀ and 10 μ l of TQ or TA at 1, 10 and 50 μ M. All the preparations were carried out at 37°C. This experiment was performed according to Riviere et al. (2007) with some modifications such as

temperature, final concentration of PBS and A β sequences.

Measurement of A β aggregation and inhibitory activity by UV-visible spectroscopy

A β aggregation and inhibitory activity was measured using a Mini UV-VIS 1240 spectrophotometer (Shimadzu, Japan). Initially, the UV spectra of TQ and TA were recorded over the range of 190 to 500 nm at 37°C in order to control any artifacts due to its own aggregation effects. Then the optimal measurements of A β ₁₋₄₀ were recorded within 190 to 500 nm at 37°C. The anti-aggregation effects of A β ₁₋₄₀, in presence of TQ or TA were monitored from 0 to 16 days at 220 nm; to observe the absorption of peptide bond. To rule out any influence due to compounds absorbance, their UV-visible spectra were subtracted from A β ₁₋₄₀ absorption spectra.

Observation of transmission electron microscopy (TEM)

After 16 days of incubation at 37°C, 20 μ l of A β ₁₋₄₀, in presence of TQ or TA were viewed under TEM. The samples were prepared on continuous carbon support films, followed by glow discharging and negative staining of 2% aqueous uranyl acetate (pH 4.5) by the single droplet procedure. The A β ₁₋₄₀ in presence of TQ or TA was adsorbed onto the carbon film for 5 min, washed with 20 μ l droplets of water and uranyl acetate solution, each and were viewed under a TEM Philips HMG 400 at 30,000 and 100,000 \times magnifications. A representative assessment of A β fibril formation was made at several positions (~10) across each EM grid, to avoid the inadvertent production of a biased/subjective data selection.

Neurotoxicity assays (MTS and LDH)

The MTS and LDH release assays, as an indicator for cell viability and cell death, respectively were performed according to our previous studies (Ismail et al., 2008).

Caspases-3, -8 and -9 activations

The caspase-3 activity was determined using Ac-DEVD-pNA, as a colorimetric specific substrate (Caspase™ Assay System, Promega) labeled with chromophore *p*-nitroaniline (pNA). Briefly, after treatment, the cells were harvested by centrifugation at 450 *g* for 10 min at 4°C. The cell pellets were kept on ice followed by resuspension in cell lysis buffer. The supernatant fraction (cell extract) was collected and 2 μ l of DEVD-pNA substrate (10 mM stock) were added to each sample. The absorbance of caspase-3 activity was measured after 4 h incubation at 37°C by microplate reader at 405 nm. Caspase-8 and -9 activities were measured using Kits, Colorimetric, from Sigma-Aldrich (St Louis, MO, USA) and Chemicon Inc., (Pennsylvania, USA), respectively. The substrates used were Ac-IETD-pNA and Ac-LEHD-pNA for caspase-8 and -9, respectively. The samples preparation was similar to caspase-3 procedure.

RESULTS AND DISCUSSION

Aggregation of A β by UV-visible spectroscopy

The A β ₁₋₄₀ spectra showed maximum absorbance at 220

nm (Figure 1A). The electromagnetic spectrum range of 190 to 220 nm was corresponded to peptide bond, whereas 280 nm for protein. A β ₁₋₄₀ showed characteristics of sigmoidal curve only at 50 and 100 μ M (Figure 1B). Thus, 50 μ M was chosen for further studies. 100 and 200 μ M A β ₂₅₋₃₅, incubated at 15°C, showed appreciable absorbance (Riviere et al., 2007). However, the absorption decreased at 50 μ M and lost at 10 μ M. The maximum decrease in absorbance was observed as incubation time was increased from 0 to 5 h, finally leading to equilibration after 5 h. In the present study, samples were incubated at 37°C; however no significant changes could be noticed within 1 h interval during first 5 h. The maximum absorbance only decreased significantly on prolonging the span of incubation up to 3 days and finally to equilibration after 6 days (Figure 1B). The decrease in absorption may be due to hidden peptide bond in macromolecular structures (Riviere et al., 2007). The differences between these two conditions may be due to different sources and peptide sequences of A β used in the experiments. In addition, our samples were incubated at 37°C as this temperature was similar to incubation of A β for toxicity study in cell culture instead of 15°C used by Riviere et al. (2007). Moreover, studies by Ono et al. (2006a, 2004a, 2003, 2004, 2005, 2006b, 2004c) and Gilead et al. (2006) used 37°C as the incubation temperature for A β ₁₋₄₀ and the equilibrium level was achieved after 6 days incubation.

TA and TQ effects on A β ₁₋₄₀ aggregation by UV-Visible spectroscopy

N. sativa has been demonstrated to have protective effects against A β -induced toxicity in neuronal cells (Ismail et al., 2008). However, disaggregation effects of its bioactive constituent, that is, TQ on A β aggregates have not been studied yet. In this study, TA was used as a reference since it showed anti-amyloidogenic effects (Ono et al., 2004c) in comparison to TQ. To verify the dose- and time-dependent effects on 50 μ M A β ₁₋₄₀ fibril inhibitions by 1, 10 and 50 μ M TA and TQ, the relative absorbance variations at 0, 5 and 16 days were measured. Percent inhibition (I %) by TA and TQ on A β fibril formation were calculated according to Riviere et al. (2007). Inhibition percentages of A β fibril formation increased with the increase in concentrations of TA and TQ in a dose-dependent manner, with small inconsistency as function of time (Figure 2). At day 0 and 5, all the TQ concentrations showed more than 50% inhibition of A β . However, 50 μ M TA showed more than 50% inhibition while 1 and 10 μ M TA did not inhibit more than 40%. Nevertheless, at day 16, TA at all the concentrations showed 100% inhibition of A β as compared to TQ, which exhibited 100% inhibition only at




Figure 1. A representative of absorbance spectra of Aβ₁₋₄₀ versus time at 37°C from 0-96 h at 190-500 nm. Reaction mixture containing 50 μM of Aβ₁₋₄₀, 0.8 mM phosphate buffer, pH 7.2 and 10 μl DMSO (A). A recording from 0-9 days at 220 nm shows the typical lag phase required for nucleation (B).




Figure 2. Inhibitory effects of tannic acid (TA) and thymoquinone (TQ) on Aβ₁₋₄₀ aggregation at 1, 10 and 50 μM concentrations within day 0, 5 and 16 of incubation at 37°C. Reaction mixtures containing 50 μM of Aβ₁₋₄₀, 0.8 mM phosphate buffer, pH 7.2 and 10 μl of TA or TQ. Means and SD of two independent experiments are shown. *Significantly different from the TA inhibitory effect (p<0.05).

Table 1. EC₅₀ of tannic acid (TA) and thymoquinone (TQ) on the formation of A β ₁₋₄₀ fibrils.

Incubation time	EC ₅₀ of TQ (μ M)	EC ₅₀ of TA (μ M)
Day 0	0.1	29
Day 5	2	26
Day 16	0.2	0.01

EC₅₀ is defined as the concentrations of TA and TQ that inhibit the formation of A β ₁₋₄₀ fibrils by 50% of the control value, which is calculated from the sigmoidal curve fitting of the data. The reaction mixtures containing 50 μ M A β ₁₋₄₀, 0.8 mM phosphate buffer, pH 7.2 and 10 μ l tannic acid (TA) or thymoquinone (TQ) at concentrations of 1, 10 and 50 μ M were incubated at 37°C for 0, 5 and 16 days.

50 μ M. Meanwhile, 1 and 10 μ M TQ inhibited A β fibrils formation by 60 and 70%, respectively. A little inconsistency needs to be probed, as mechanism is still unclear. But, it may be hypothesized that 10 μ M TA might have inhibited slowly due to some structure-activity relationships following stoichiometric balancing at the said concentration. The effective concentrations at 50% value (IC₅₀) of TA and TQ are shown in Table 1. IC₅₀ is defined as the concentrations of TA and TQ, which inhibited the formation of A β ₁₋₄₀ fibrils by 50% of the control value, calculated from the sigmoidal curve fitting in data.

Observation on TA and TQ effects on A β ₁₋₄₀ aggregation under TEM

After incubation of 50 μ M A β ₁₋₄₀ at 37°C for 16 days, extensive formations of fibrils were observed under TEM (Figure 3G). Protofibrils were formed during first week of A β ₁₋₄₀ incubation before mature fibrils were generated (Harper et al., 1999). Therefore, in the present study, we observed mature fibrils formation after incubation of 2 weeks. This result was supported by Cohen et al. (2006) and Gilead et al. (2006), who stated that A β should be incubated at 37 °C for at least 14 days to achieve a steady state (maximal) level of fibrillization. When 50 μ M A β ₁₋₄₀ were co-incubated with 1, 10 and 50 μ M of TA or TQ, the number of fibrils were reduced in some degree with shorter fibrils and small amorphous aggregates (Figure 3A to F).

Our findings showed that TQ could be a promising A β inhibitor. Its inhibitory effects were slightly similar to TA at day 16 (Table 1). TQ is a non-polar molecule which was dissolved well in organic solvent (acetone). Therefore, it is postulated that the binding between TQ and A β ₁₋₄₀ could be induced by hydrophobic interactions of TQ and hydrophobic region of A β . Thus blocking the associations between A β molecules and thereby inhibiting the fibril formation. These interactions could be reinforced by the H-bond acceptor group of TQ (Figure 4) with some donor

groups from A β . The same interactions have been suggested for resveratrol (Riviere et al., 2007). In addition, the hydrophobic regions of A β could interact with lipophilic chain of TQ, as occurred between A β and rifampicin (Ono et al., 2006b). On the other hand, TA also showed anti-amyloidogenic activity in the present study, as indicated by Ono et al. (2004c) previously. This anti-amyloidogenic effect may depend on their molecular structure. Tannic acid is a flexible bulk molecule with rings containing numerous hydroxyl groups (Figure 4). The number of hydroxyl groups of these polyphenols maybe responsible for its inhibitory effect on A β fibril formation (Ono et al., 2003). However, a large molecule of tetracycline possessed a weak anti-amyloidogenic activity (Ono et al., 2004c).

On the other hand, resveratrol and curcumin were among the small molecules that were effective as anti-amyloidogenic agents (Riviere et al., 2007; Ono et al., 2004a). The molecular weight of TQ was much smaller than resveratrol and curcumin. Thymoquinone may have other mechanisms in inhibition of A β fibrils formation since its structure does not contain any hydroxyl groups and it is smaller in size than resveratrol and curcumin. Aromatic ring of TQ may also be suspected to be responsible for inhibition. Thus, TQ may have some properties in such a way to prevent A β aggregation.

Protective effects of TQ on A β ₁₋₄₀-induced toxicity (MTS and LDH assays)

Exposure of CGNs to aged 10 μ M A β ₁₋₄₀ at 37°C showed inhibition of cell viability by MTS assay to 54 \pm 0.98% ($p < 0.01$) for 4 days of profibrils formation (Figure 5). As stated by Durairajan et al. (2008), the death rate increases with the aging time of A β fibrils. In this study, A β ₁₋₄₀-induced toxicity was attenuated by pretreatment with TQ in a dose-dependent way. Thymoquinone at 0.1 and 1 μ M restored the cells viability of CGNs against aged A β ₁₋₄₀-induced toxicity by 99 \pm 2.31 and 91 \pm 1.92%, respectively ($p < 0.01$). Treatment of TQ alone did not affect the growth of CGNs within tested concentrations. To further confirm the MTS finding, LDH assay was performed. Exposure of CGNs to 10 μ M A β ₁₋₄₀ increased LDH activity by 117.00 \pm 0.74% as compared to control (Figure 5). Pretreatment with 0.1 and 1 μ M TQ significantly protected the neurotoxicity induced by A β ₁₋₄₀ (61 \pm 2.05 and 65 \pm 3.09%, respectively) compared to A β ₁₋₄₀ alone. Thus, the findings from MTS and LDH assays showed that TQ, even at low doses, was able to protect the cells against toxicity of A β ₁₋₄₀.

TQ reduced the activation of caspases-3, -8 and -9 on A β ₁₋₄₀ exposure

Figure 6 shows an increment of caspase-3 activity after




Figure 3. Electron micrographs of $A\beta_{1-40}$ fibrils. The reaction mixtures containing $50 \mu\text{M } A\beta_{1-40}$, 0.8 mM phosphate buffer, $\text{pH } 7.2$ and $10 \mu\text{l}$ tannic acid (TA) or thymoquinone (TQ) incubated at 37°C . (A) $50 \mu\text{M } A\beta_{1-40} + 1 \mu\text{M TA}$ (B) $50 \mu\text{M } A\beta_{1-40} + 10 \mu\text{M TA}$ (C) $50 \mu\text{M } A\beta_{1-40} + 50 \mu\text{M TA}$ (D) $50 \mu\text{M } A\beta_{1-40} + 1 \mu\text{M TQ}$ (E) $50 \mu\text{M } A\beta_{1-40} + 10 \mu\text{M TQ}$ (F) $50 \mu\text{M } A\beta_{1-40} + 50 \mu\text{M TQ}$ (G) $A\beta_{1-40}$ alone. The bar represents 200 nm .

exposure to $10 \mu\text{M } A\beta_{1-40}$ for 24 h. Pre-treatment of CGNs with $0.1 \mu\text{M TQ}$ for 5 h before exposure to $10 \mu\text{M } A\beta_{1-40}$ was able to reduce caspase-3 activity from 115 ± 1.09 to $87 \pm 5.76\%$, significantly. Incubation of TQ alone had no effect on caspase-3 activity. Hence, the efficiency of TQ in reducing caspase-3 activation was further examined on its ability to inhibit caspase-8 and -9 activations.

Caspase-8 was localized at the top of hierarchy of

caspase cascade and a member of the upstream or initiator family of caspases. Caspase-8 activated downstream caspases (3, 6, and 7) that cleaved key cellular substrates and led to apoptotic cells death. Figure 6 shows significant differences in caspase-8 activation ($111 \pm 6.82\%$) of $A\beta$ exposed to CGNs compared to control. However, $0.1 \mu\text{M TQ}$ was able to reduce the caspase-8 activity to $83 \pm 5.08\%$. $A\beta$ induced apoptosis




Figure 4. Structure of TQ and TA.




Figure 5. Neuroprotective effect of TQ against Aβ₁₋₄₀. The CGNs were pretreated for 5 h with thymoquinone (TQ) at concentrations of 0.1 and 1 μM before being exposed to 10 μM Aβ₁₋₄₀ for 24 h and measured using MTS and LDH assays. The percentage of DMSO was at 0.01% (v/v). Values represent means ± S.E.M. *P<0.01 versus Aβ₁₋₄₀, #P<0.01 versus control.

in the AD brain led to caspase-8 activation by cross-linking and activating the death-receptor. Rohn et al. (2001) stated that many cell types were sensitive to receptor-mediated apoptosis followed by oligomerization of receptors on cell surface. Ivins et al. (1999) showed Aβ

toxicity induced apoptosis by causing receptor oligomerization and activated the caspase-8. The neurotoxic action of Aβ involved the fibrillar features of Aβ (Cribbs et al., 1997). Fibrillar Aβ may prompt neuronal cell death associated with AD by induction of apoptosis




Figure 6. Thymoquinone (TQ) reduced the Aβ₁₋₄₀-induced activation of caspases-3, -8 and -9 in CGNs. Caspases activities were determined for 24 h in untreated and cells treated with 10 μM Aβ₁₋₄₀ alone or 10 μM Aβ₁₋₄₀ + 0.1 μM TQ. Values represent means ± S.E.M. [#]P<0.01 versus control, ^{*}P<0.01 versus Aβ₁₋₄₀.

followed by cross-linking of death-receptors and concomitant activation of caspase-8 and caspase-3.

An alternative pathway of Aβ-induced apoptosis, in neuron culture, also involved the caspase-9 activation. Exposure of CGNs to 10 μM Aβ₁₋₄₀ for 24 h activated the caspase-9 (148 ± 8.32%). Thymoquinone (0.1 μM) reduced caspase-9 activation to 95 ± 5.34%, significantly ($p < 0.01$) (Figure 6). Oxidative damage is the key feature of normal aging but more extensive in the AD brain (Smith et al., 2000). Extensive oxidative insults accumulated by neurons may have selectively undergone apoptosis (Lu et al., 2000). Mitochondria were particularly vulnerable to oxidative damage, as it produced major sources of oxidants through normal metabolic processes. Mitochondrial dysfunction has been observed in AD brain (Hirai et al., 2001), and as a consequence, stimulation of mitochondrial pathway of apoptosis may be elicited through oxidative damage leading to release of cytochrome c. Released cytochrome c interacted with Apaf-1 and this complex recruited caspase-9 activations (Kuida, 2000).

In this study, 10 μM Aβ₁₋₄₀ was found capable to activate apoptosis via both extrinsic and intrinsic pathways. Caspase-8 activation was slightly increased, whereas caspase-9 showed marked activations as compared to control. These findings indicate the potential of TQ in reducing the activation of both caspase-8 and -9. In conclusion, these results indicate the protective effects of TQ on CGNs may be due to its contribution in

disaggregating the neurotoxic Aβ accumulation, thus protecting cells from cell death.

ACKNOWLEDGMENTS

Authors are thankful to Government of Malaysia and Universiti Putra Malaysia for providing financial and technical supports for this work via Research University Grant.

REFERENCES

- Anekonda TS, Reddy PH (2005). Can herbs provide a new generation of drugs for treating Alzheimer's disease? *Brain Res. Rev.* 50:361-376.
- Benzi G, Moretti A (1998). Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? *Eur. J. Pharmacol.* 346:1-13.
- Cohen T, Frydman-Marom A, Rechter M, Gazit E (2006). Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. *Biochem.* 45:4727-4735.
- Cribbs DH, Pike CJ, Weinstein SL, Velazquez P, Cotman CW (1997). All-D-enantiomers of β-amyloid exhibit similar biological properties to all-L-β-amyloids. *J. Biol. Chem.* 272:7431-7436.
- De Ruvo C, Amodio R, Algeri S, Martelli N, Intilangelo A, D'Ancona GM et al. (2000). Nutritional antioxidants as antidegenerative agents. *Int. J. Dev. Neurosci.* 18:359-66.
- Durairajan SSK, Yuan Q, Xie L, Chan WS, Kum WF, Koo I (2008). Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ-induced cytotoxicity. *Neurochem. Int.* 52(4-5):741-750.

- Gilead S, Wolfenson H, Gazit E (2006). Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin. *Angew. Chem. Int. Ed Engl.* 45:6476–6480.
- Grundman M, Delaney P (2002). Antioxidant strategies for Alzheimer's disease. *Proc. Nutr. Soc.* 61:191-202.
- Hardy JA, Higgins GA (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science* 256:184–185.
- Harper JD, Wong SS, Lieber CM, Lansbury PT (1999). Assembly of A β amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease. *Biochem.* 38:8972-8980.
- Harper JD, Lansbury Jr PT (1997). Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. *Ann. Rev. Biochem.* 66:385-407.
- Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA (1994). A model for beta amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* 91:3270-3274.
- Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS (2001). Mitochondrial abnormalities in Alzheimer's disease. *J. Neurosci.* 21(9):3017-3023.
- Hirohata M, Ono K, Naiki H, Yamada M (2005). Non-steroidal anti-inflammatory drugs have anti amyloidogenic effects for Alzheimer's β -amyloid fibrils in vitro. *Neuropharmacology* 49:1088-1099.
- Inanami O, Watanabe Y, Syuto B, Nakano M, Tsuji M, Kuwabara M (1998). Oral administration of (+)-catechin protects against ischemia-reperfusion-induced neuronal death in the Gerbil. *Free Rad. Res.* 29:359–365.
- Irie Y, Keung WM (2003). *Rhizoma acori graminei* and its active principles protect PC-12 cells from the toxic effect of amyloid- β peptide. *Brain Res.* 963:282-28.
- Ismail N, Ismail M, A.Latiff L, Mazlan M, Abdalbasit AM (2008). Black cumin seed (*Nigella sativa* Linn.) oil and its fractions protect against beta amyloid peptide-induced toxicity in primary cerebellar granule neurons. *J. Food Lipids* 15(4):519-533.
- Ivins KJ, Thornton PL, Rohn TT, Cotman CW (1999). Neuronal apoptosis induced by β -amyloid is mediated by caspase-8. *Neurobiol. Dis.* 6:440–449.
- Jeong JC, Yoon CH, Lee WH, Park KK, Chang YC, Choi YH, Kim CH (2005). Effects of *Bambusae concretio* Salicea (Chunchukhwang) on amyloid β -induced cell toxicity and antioxidative enzymes in cultured rat neuronal astrocytes. *J. Ethnopharmacol.* 98:259-266.
- Kuida K (2000). Caspase-9. *Int. J. Biochem. Cell Biol.* 32:121–124.
- Kumar MHV, Gupta YK, (2003). Effect of *Centella asiatica* on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats. *Clin. and Exp. Pharmacol. Physiol.* 30:336-342.
- Lai SW, Yu MS, Yuen W, Hu C, Raymond CC (2006). Novel neuroprotective effects of the aqueous extracts from *Verbena officinalis* Linn. *Neuropharmacology* 50:641-650.
- Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH, Bredesen DE (2000). A second cytotoxic proteolytic peptide derived from amyloid beta protein precursor. *Nat. Med.* 6:397–404.
- Luchsinger JA, Mayeux R (2004). Dietary factors and Alzheimer's disease. *Lancet Neurol.* 3:579-587.
- Naiki H, Hasegawa K, Yamaguchi I, Nakamura H, Gejyo F, Nakakuki K (1998). Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's β -amyloid fibril formation in vitro. *Biochemistry* 37:17882-17889.
- Okuda T, Kimura Y, Yoshida T, Hatano T, Okuda H, Arichi S (1983). Studies on the activities of tannins and related compounds from medicinal plants and drugs: I. Inhibitory effects on lipid peroxidation in mitochondria and microsomes of liver. *Chem. Pharm. Bull.* 31:1625–1631.
- Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M (2003). Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. *J. Neurochem.* 87:172-181.
- Ono K, Hasegawa K, Naiki H, Yamada M (2004a). Curcumin has potent anti-amyloidogenic effects for Alzheimer's β -amyloid fibrils in vitro. *J. Neurosci. Res.* 75:742-750.
- Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M (2004b). Vitamin A exhibits potent anti-amyloidogenic and fibril-destabilizing effects in vitro. *Exp. Neurol.* 189:380-392.
- Ono K, Hasegawa K, Naiki H, Yamada M (2004c). Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's β -amyloid fibrils in vitro. *Biochim. Biophys. Acta* 1690:193-202.
- Ono K, Hasegawa K, Naiki H, Yamada M (2005). Preformed β -amyloid fibrils are destabilized by coenzyme Q₁₀ in vitro. *Biochem. Biophys. Res. Commun.* 330:111-116.
- Ono K, Hasegawa K, Naiki H, Yamada M (2006a). Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's β -amyloid fibrils in vitro. *Neurochem. Int.* 48:275-285.
- Ono K, Hirohata M, Yamada M (2006b). α -Lipoic acid exhibits anti-amyloidogenicity for β -amyloid fibrils in vitro. *Biochem. Biophys. Res. Commun.* 341:1046-1052.
- Riviere C, Richard T, Quentin L, Krisa S, Merillon JM, Monti JP (2007). Inhibitory activity of stilbenes on Alzheimer's β -amyloid fibrils in vitro. *Bioorg. Med. Chem.* 15:1160-1167.
- Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ et al. (1996). Morphology and toxicity of A β (1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. *J. Biol. Chem.* 271:20631-20635.
- Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH (2001). Activation of caspase-8 in the Alzheimer's disease brain. *Neurobiol. Dis.* 8:1006–1016.
- Salem ML (2005). Immunomodulatory and therapeutic properties of the *Nigella sativa* L. seed. *Int. Immunopharmacol.* 5:1749–1770.
- Selkoe DJ (1999). Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature* 399:A23–A31.
- Shutenko Z, Henry Y, Pinard E, Seylaz J, Potier P, Berthet F, et al. (1999). Influence of the antioxidant quercetin *in vivo* on the level of nitric oxide determined by electron paramagnetic resonance in rat brain during global ischemia and reperfusion. *Biochem. Pharmacol.* 57:199–208.
- Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000). Oxidative stress in Alzheimer's disease. *Biochim. Biophys. Acta* 1502:139-144.
- Sudhir K (2004). Memantine: Pharmacological properties and clinical uses. *Neurol. India* 52:307-309.
- Sun GY, Xia J, Draczynska-Lusiak B, Simonyi A, Sun AY (1999). Grape polyphenols protect neurodegenerative changes induced by chronic ethanol administration. *Neuroreport* 10:93–96.
- Ward RV, Jennings KH, Jepras R, Neville W, Owen DE, Hawkins J, Christie G, Davis JB, George A, Karran EH, Howlett DR (2000). Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β -amyloid peptide. *Biochem. J.* 348:137-144.
- Yankner BA (1996). Mechanisms of neuronal degeneration in Alzheimer's disease. *Neuron* 16:921–932.
- Yu MS, Leung SKY, Lai SW, Che CM, Zee SY, So KF, Yuen WH, Chang RCC (2005). Neuroprotective effects of anti-aging oriental medicine *Lycium barbarum* against β -amyloid peptide neurotoxicity. *Exp. Gerontol.* 40:716-727.